Controller medications, also known as daily maintenance medications, are a critical tool for managing asthma — reducing daily ...

However, early versions of fatty spheres for mRNA delivery won’t work for inhalable medications because the nanoparticles ...

COPD management typically involves medications like bronchodilators ... AMGN/AstraZeneca’s tezepelumab, and GSK’s mepolizumab ...

Though prescribing climate-friendly inhalers is environmentally sound, some experts warn certain patients may be overlooked.

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

The association added that it would review the proposed order and submit comments accordingly. Tylenol maker Kenvue, GSK, ...

Abbott India continued to benefit from anti-infectives and medications for gastrointestinal conditions, the company said ...

Drugmaker Abbott India reported a rise in second-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications.

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...

GSK plc GSK reported third-quarter 2024 core earnings of $1.27 per American depositary share (ADS), which beat the Zacks Consensus Estimate of $1.16. Core earnings declined 1% year over year on a ...

Welcome to today's call and webcast. The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to Slide 2. This is the usual safe harbor ...